Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors [PDF]
New England Journal of Medicine, 2002 BACKGROUND Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical
George D. Demetri +20 more
openalex +2 more sources
A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome [PDF]
New England Journal of Medicine, 2003 BACKGROUND Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause.
Jan Cools +25 more
openalex +2 more sources
Haematologica, 2016 The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed.
Sung-Eun Lee +20 more
doaj +2 more sources
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels [PDF]
Blood, 2003 Corbin and colleagues analyze in their report[1][1] the biochemical and biologic effects of several mutations in the kinase domain of the Bcr-Abl protein identified in patients who developed resistance to imatinib.
Carlo Gambacorti‐Passerini +2 more
openalex +3 more sources
The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience [PDF]
Vojnosanitetski Pregled, 2021 Background/Aim. The treatment of chronic myeloid leukemia (CML) has changed dramatically with the advent of targeted therapies. This study aimed to assess the efficacy of generic imatinib in CML patients treated in our center. Methods.
Urošević Ivana +9 more
doaj +1 more source
Case Reports in Oncology, 2021 Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse drug reaction; reported cases are sometimes imatinib mesylate induced.
Hyerin Park, Gil-Soon Choi, Eun Mi Lee
doaj +1 more source
Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. [PDF]
PLoS ONE, 2014 Despite the benefits of imatinib for treating gastrointestinal stromal tumors (GIST), the prognosis for high risk GIST and imatinib-resistant (IR) GIST remains poor. The mechanisms of imatinib resistance have not yet been fully clarified.
Hiroyuki Sako +9 more
doaj +1 more source
Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. [PDF]
PLoS Pathogens, 2015 Imatinib mesylate (Gleevec) inhibits Abl1, c-Kit, and related protein tyrosine kinases (PTKs) and serves as a therapeutic for chronic myelogenous leukemia and gastrointestinal stromal tumors.
Ruth J Napier +16 more
doaj +1 more source
Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation. [PDF]
PLoS ONE, 2013 Imatinib can induce complete molecular remission (CMR) in relapse chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation, but it is indefinite whether imatinib is required to maintain CMR.
Hua Jin +11 more
doaj +1 more source
Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice. [PDF]
PLoS ONE, 2014 Recent studies indicate that tyrosine kinase inhibitors, including imatinib, can reverse hyperglycemia in non-obese diabetic (NOD) mice, a model of type 1 diabetes (T1D). Imatinib inhibits c-Abl, c-Kit, and PDGFRs.
Janet Lau +5 more
doaj +1 more source